Specific disruption of NFAT5 or NF-kappaB binding sites in the LTR of HIV-1 subtype B.

(A) Mutations introduced into a HIV-1Lai/Bal-env infectious molecular clone.
# T1 Protein S2 45 48 132 135 env

NF-kappaB and NFAT5 binding site mutations were introduced into the LTR of the HIV-1Lai/Bal-env-wild type (WT) infectious molecular clone.
# T2 Protein S3 92 95 256 259 env

The NF-kappaB binding site mutants (HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, HIV-1Lai/Bal-env-kappaB I+II-Mut), and NFAT5 binding site mutant (HIV-1Lai/Bal-env-N5-Mut) are shown along with the HIV-1Lai/Bal-env-WT sequence.
# T3 Protein S4 49 52 352 355 env
# T4 Protein S4 80 83 383 386 env
# T5 Protein S4 112 115 415 418 env
# T6 Protein S4 178 181 481 484 env
# T7 Protein S4 228 231 531 534 env

Mutations were introduced into the 3' LTR of the HIV-1Lai/Bal-env-WT proviral sequence.
# T8 Protein S5 62 65 610 613 env

(B) Specific mutation of the NFAT5 binding site abolishes NFAT5 binding to the viral LTR but does not affect NF-kappaB p50/p65 binding to the overlapping NF-kappaB binding site.
# T9 Protein S6 58 63 694 699 NFAT5
# T10 Protein S6 119 122 755 758 p50
# T11 Protein S6 123 126 759 762 p65

Quantitative DNaseI footprinting analysis is shown using HIV-1 LTR fragments (-262 to +4 nt relative to the transcription start site) from HIV-1Lai/Bal-env-WT and HIV-1Lai/Bal-env-N5-Mut and increasing concentrations of recombinant NF-kappaB (p50/p65) (25 ng, 100 ng, and 500 ng), or NFAT5 (10 ng, 50 ng, and 250 ng).
# T12 Protein S7 13 19 827 833 DNaseI
# T13 Protein S7 152 155 966 969 env
# T14 Protein S7 176 179 990 993 env
# T15 Protein S7 243 246 1057 1060 p50
# T16 Protein S7 247 250 1061 1064 p65
# T17 Protein S7 284 289 1098 1103 NFAT5

The regions that are protected from DNase I cleavage by the binding of NF-kappaB and NFAT5 are indicated with a bars.
# T18 Protein S8 36 43 1168 1175 DNase I
# T19 Protein S8 85 90 1217 1222 NFAT5

(C) Specific disruption of the HIV-1 subtype B NF-kappaB binding sites effectively abrogates recombinant p50/p65 binding.
# T20 Protein S9 105 108 1355 1358 p50
# T21 Protein S9 109 112 1359 1362 p65

Quantitative DNaseI footprinting analysis is shown of nucleotides -262 to +4 from HIV-1Lai/Bal-env-WT, HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, and HIV-1Lai/Bal-env-kappaB I+II-Mut and increasing concentrations of recombinant NF-kappaB (p50/p65) (25 ng, 100 ng, and 500 ng).
# T22 Protein S10 13 19 1385 1391 DNaseI
# T23 Protein S10 95 98 1467 1470 env
# T24 Protein S10 116 119 1488 1491 env
# T25 Protein S10 147 150 1519 1522 env
# T26 Protein S10 183 186 1555 1558 env
# T27 Protein S10 259 262 1631 1634 p50
# T28 Protein S10 263 266 1635 1638 p65

The regions that are protected from DNase I cleavage by the binding of recombinant NF-kappaB are indicated with a bars.
# T29 Protein S11 36 43 1705 1712 DNase I

(D) Specific disruption of the HIV-1 subtype B NF-kappaB binding site does not inhibit but enhances NFAT5 binding to this region.
# T30 Protein S12 100 105 1889 1894 NFAT5

Quantitative DNaseI footprinting analysis is shown of nucleotides -262 to +4 from HIV-1Lai/Bal-env-WT, HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, and HIV-1Lai/Bal-env-kappaB I+II-Mut and increasing concentrations of recombinant NFAT5 (10 ng, 50 ng, and 250 ng).
# T31 Protein S13 13 19 1932 1938 DNaseI
# T32 Protein S13 95 98 2014 2017 env
# T33 Protein S13 116 119 2035 2038 env
# T34 Protein S13 147 150 2066 2069 env
# T35 Protein S13 183 186 2102 2105 env
# T36 Protein S13 248 253 2167 2172 NFAT5

The regions that are protected from DNase I cleavage by the binding of recombinant NFAT5 are indicated with a bars.
# T37 Protein S14 36 43 2237 2244 DNase I
# T38 Protein S14 83 88 2284 2289 NFAT5

